WHO releases groundbreaking global guidelines on GLP-1 medications for obesity treatment, sparking worldwide attention

DCM Editorial Summary: This story has been independently rewritten and summarised for DCM readers to highlight key developments relevant to the region. Original reporting by WHO, click this post to read the original article.

To help tackle the global obesity crisis, which currently affects over 1 billion people and leads to millions of deaths each year, the World Health Organization (WHO) has issued its first guideline for using GLP-1 therapies. These medications, previously added to WHO’s Essential Medicines List for type 2 diabetes, are now conditionally recommended for the long-term treatment of obesity in adults. If you’re struggling with obesity, this guideline recognizes it as a chronic disease, urging a comprehensive approach that includes medication, a healthier diet, regular physical activity, and ongoing professional support.

GLP-1 therapies, including liraglutide, semaglutide, and tirzepatide, have shown effectiveness in treating obesity and improving metabolic health. However, WHO’s recommendation is conditional due to high costs, limited long-term data, and health system readiness. If you’re considering this treatment, know that it’s not a standalone solution. The guideline suggests combining GLP-1 therapy with behavioral interventions like structured diet and exercise plans to help improve results.

You should understand that addressing obesity requires more than just medication—it demands wider societal and policy changes. WHO outlines the need for a full-scale approach that creates healthier environments, focuses on early intervention for high-risk groups, and ensures long-term, personalized care for those affected. These strategies aim to change how obesity is managed at both individual and national levels.

With the demand for GLP-1 therapies growing fast, there’s also concern about unequal access and the rise of fake or poor-quality medications. WHO stresses the importance of keeping the drug supply safe and making treatments more affordable. They’re calling for efforts like pooled procurement and licensing agreements to help ensure these therapies reach those who need them most—especially in places where access remains limited.

Finally, if you’re someone impacted by obesity, know that WHO created these guidelines through deep research and consultation with experts and people living with the condition. The effort is part of a broader plan to stop the rise of obesity and reduce its impact. WHO will keep updating the guidance as new information emerges, always aiming to provide clear and equitable solutions worldwide.